<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82699">
  <stage>Registered</stage>
  <submitdate>27/03/2008</submitdate>
  <approvaldate>4/04/2008</approvaldate>
  <actrnumber>ACTRN12608000167369</actrnumber>
  <trial_identification>
    <studytitle>A study to investigate the effects of nebulised magnesium in severe exacerbations of Chronic Obstructive Pulmonary Disease (COPD)</studytitle>
    <scientifictitle>A randomised, double-blind, parallel group, placebo-controlled study investigating the efficacy and tolerability of adjuvant nebulised magnesium therapy in conjunction with standard emergency department treatment of acute severe exacerbations of Chronic Obstructive Pulmonary Disease (COPD)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Not applicable</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease (COPD)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The treatment intervention is 2.5ml of 0.25mmol/mL magnesium sulphate solution given as a nebulised inhalation on 3 occasions (total dose 0.625mmol). The 3 doses are administered at time (T) = 0min, T= 30min and T = 60min. Subjects will also receive standard therapy for a severe COPD exacerbation in accordance with emergency department protocols and their clinical presentation.</interventions>
    <comparator>The control is neublised isotonic saline (placebo)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Forced Expiratory Volume in 1 second (FEV1) in litres/minute measured by handheld spirometer</outcome>
      <timepoint>At 30 minutes, 60 minutes and 90 minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Combined endpoint of FEV1 at 90 minutes minutes and hospital admission in subjects with life-threatening COPD (FEV1 &lt;30% predicted at randomisation)</outcome>
      <timepoint>90 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospital admission</outcome>
      <timepoint>Measured throughout stay in the emergency department</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Requirement for non-invasive or invasive ventilation.</outcome>
      <timepoint>Measured throughout stay in the emergency department and hospital ward if admitted</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Admission to the Intensive Care Unit (ICU)</outcome>
      <timepoint>Measured throughout stay in the emergency department and hospital ward if admitted</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality at 30 days</outcome>
      <timepoint>Mortality will be assessed 30 days after the presentation to the Emergency Department</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Aged greater than 35 years old; Doctor diagnosis of COPD, emphysema or chronic bronchitis; Presentation to the Emergency Department (ED) with a severe exacerbation of COPD (initial FEV1 &lt; or = 50% predicted)</inclusivecriteria>
    <inclusiveminage>36</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients requiring intubation or non-invasive ventilation on arrival, or too unwell to perform spirometry at presentation; Another serious medical condition that would prevent their participation in the trial; Pregnant women; Pneumothorax</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>22/05/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Medical Research Institute of New Zealand</primarysponsorname>
    <primarysponsoraddress>Level 7 CSB Building
Wellington Regional Hospital
Riddiford Street
Newtown
Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541,
Wellesley Street,
Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Level 2, 1-3 The Terrace
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>15/02/2008</ethicapprovaldate>
      <hrec>CEN/07/12/087</hrec>
      <ethicsubmitdate>26/11/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Kyle Perrin</name>
      <address>Medical Research Institute of New Zealand
Level 7 CSB Building
Wellington Regional Hospital
Wellington 6021</address>
      <phone>+64 4 805 0147</phone>
      <fax />
      <email>kyle.perrin@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kyle Perrin</name>
      <address>Medical Research Institute of New Zealand
Level 7 CSB Building
Wellington Regional Hospital
Wellington 6021</address>
      <phone>+64 4 805 0147</phone>
      <fax />
      <email>kyle.perrin@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kyle Perrin</name>
      <address>Medical Research Institute of New Zealand
Level 7 CSB Building
Wellington Regional Hospital
Wellington 6021</address>
      <phone>+64 4 805 0147</phone>
      <fax />
      <email>kyle.perrin@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>